Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study CONCLUSIONS: Fruquintinib delayed TTD of ECOG PS and did not negatively impact HRQoL versus … ← Cerium-doped mesoporous bioactive glass nanoparticles reduce oxidative stress and adipogenic differentiation in human bone marrow-derived mesenchymal stromal cells Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancer →